Alkermes PLC
(NAS:ALKS)
$
29.65
0.15 (0.51%)
Market Cap: 4.80 Bil
Enterprise Value: 4.25 Bil
PE Ratio: 15.21
PB Ratio: 3.71
GF Score: 69/100 Alkermes Plc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021 / 02:30PM GMT
Release Date Price:
$22.96
(+0.90%)
Terence C. Flynn
Goldman Sachs Group, Inc., Research Division - MD
Hi. Good morning, everybody. Thanks for joining us. I'm Terence Flynn, the U.S. biopharma analyst here at Goldman Sachs, and we're very pleased to be hosting Alkermes today at our virtual conference.
Today from the company, we have Richard Pops, who is Chairman and CEO of Alkermes. Rich, thanks so much for taking the time out of your day to join us today. I'll turn it over to you for some opening remarks, and then we'll launch into some Q&A.
Richard F. Pops
Alkermes plc - Chairman & CEO
Perfect. Great. Thanks. It's good to see you, Terence. And sorry, we're not all in person. But as we said before, this may be the last time we have to do it this way. So let's hope that's the case.
Terence C. Flynn
Goldman Sachs Group, Inc., Research Division - MD
Fingers crossed.
Richard F. Pops
Alkermes plc - Chairman & CEO
I won't take long because I'd rather have the conversation, but I just
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot